PMID: 7439251Oct 1, 1980Paper

Effects and plasma levels of propranolol and metoprolol in hyperthyroid patients

European Journal of Clinical Pharmacology
O R NilssonL Tegler

Abstract

The effects and plasma concentrations of different doses of propranolol and metoprolol were studied in 34 hyperthyroid patients. The initial daily doses were propranolol 160 mg or metoprolol 200 mg. If the resting heart rate remained above 75 beats per min after treatment for 4-7 days, the dose was increased and the patient re-examined after a further 4-7 days. Propranolol (n = 17) caused a reduced heart rate, a decrease in serum 3,3',5-triiodothyronine (T3) and an increase in serum 3,3',5'-triiodothyronine (reverse T3, rT3). In 10 patients, there was no change in T3 or rT3 until the daily dose of propranolol had been increased to 240 or 320 mg. The plasma level of propranolol was significantly correlated with the decrease in T3 and the increase in rT3. Metoprolol (n = 17) caused a reduction in heart rate similar to that following propranolol. However, serum T3 was only slightly reduced even after an increase in dose to 300 or 400 mg, and serum rT3 was not altered. Metoprolol concentrations were not significantly correlated with the fall in T3. It appears that the influence of beta-blockers on T4 conversion is of little importance for the clinical improvement in hyperthyroid patients, and rather it is a consequence of beta 1-ad...Continue Reading

References

Oct 1, 1975·British Journal of Clinical Pharmacology·I Ramsay
Aug 13, 1977·Lancet·P TheiladeK Siersbaek-Nielsen
Sep 1, 1978·British Journal of Clinical Pharmacology·D G McDevitt, J K Nelson
Dec 1, 1979·British Journal of Clinical Pharmacology·L E MurchisonP D Bewsher
May 1, 1979·Clinical Endocrinology·J FeelyJ Crooks
May 1, 1977·The Journal of Clinical Endocrinology and Metabolism·R P VerhoevenM A Schalekamp
Jun 1, 1977·Clinical Endocrinology·G LottiA Masala
Jan 1, 1978·Acta Medica Scandinavica·G KallnerM Tryselius
Feb 15, 1979·The New England Journal of Medicine·S RubenfeldP O Kohler
Apr 1, 1976·British Journal of Clinical Pharmacology·L E MurchisonW R Ferrier
Aug 1, 1977·The Journal of Clinical Endocrinology and Metabolism·W M Wiersinga, J L Touber
Sep 22, 1977·The New England Journal of Medicine·R HellmanW D Mason
Jan 1, 1975·Acta Pharmacologica Et Toxicologica·M Ervik
Aug 7, 1975·The New England Journal of Medicine·D G Shand
May 17, 1969·Lancet·R G ShanksD A Montgomery
Jun 1, 1971·Annals of Internal Medicine·W GrossmanL Dexter
Mar 24, 1972·Biochemical and Biophysical Research Communications·T MitsumaC S Hollander
Jul 1, 1981·British Journal of Clinical Pharmacology·J FeelyI H Stevenson

❮ Previous
Next ❯

Citations

Jan 1, 1982·European Journal of Clinical Pharmacology·B HallengrenE Wåhlin-Boll
Jan 1, 1991·Thyroid : Official Journal of the American Thyroid Association·W M Wiersinga
Mar 1, 1990·Clinical Endocrinology·O EberP Költringer
Jul 1, 1992·The American Journal of Medicine·D L Geffner, J M Hershman
Jun 1, 1983·Journal of Clinical and Hospital Pharmacy·M J Kendall, S R Smith
Jun 1, 1982·British Journal of Clinical Pharmacology·N R PedenJ Crooks
Jan 1, 1991·Acta Diabetologica·D E MatthewsV Kvetan
Jan 1, 1983·Acta Medica Scandinavica. Supplementum·O R Nilsson, B E Karlberg
Apr 1, 1982·British Journal of Clinical Pharmacology·B HallengrenA Melander

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.